Transfusion Medicine and Therapeutic Pathology

Overview

The Division of Transfusion Medicine and Therapeutic Pathology, serving as the therapeutic arm of the Department of Pathology and Laboratory Medicine, comprises the Hospital of the University of Pennsylvania (HUP) blood bank and transfusion service, an immunohematology reference laboratory, an apheresis unit, a hematopoietic progenitor cell processing laboratory, and two GMP Clinical Cell & Vaccine Production Facilities (CVPF) for the manufacture of novel cell therapies. Its facilities and programs are accredited by the AABB, FACT, and CAP.

The Division’s very active clinical services provide over 75,000 blood products per year to HUP patients through the blood bank and transfusion service while performing over 7,000 procedures per year in the Apheresis Clinic on both outpatients and inpatients diagnosed with a variety of hematopoietic, immunologic, oncologic, metabolic, and genetic conditions. The Division’s hematopoietic progenitor laboratory processes and reinfuses over 900 stem cells and FDA-approved CAR-T products per year. The CVPF GMP facilities currently support the manufacture of novel cell therapies for dozens of Penn Medicine clinical trials in the areas of cell and gene therapy.

The Division consists of eight faculty members who provide medical oversight and consultation for these clinical activities and/or facilitate numerous interdepartmental clinical trials and translational research efforts. Each faculty member has their individual area of academic interest and receives support through funding from the National Institutes of Health (NIH), private industry, and non-profit foundations.

Highlights

  • 24/7 comprehensive physician consultative services in transfusion medicine
  • State-of the-art therapeutic apheresis procedures, including lipoprotein apheresis
  • Novel hematopoietic stem cell collection and cell processing procedures, including those for hematopoietic cell reconstitution and adoptive immunotherapy including all FDA-approved CAR-T therapies
  • Manufacture and release testing of hundreds of engineered cell therapy products per year including novel CAR-T cells, dendritic cell vaccines, CRISPR-edited cells, and other products for treating cancer, autoimmune diseases, and infectious diseases

Faculty listing

Nicole Aqui, MD – Director, Transfusion Medicine and Therapeutic Pathology
Vijay Bhoj, MD, PhD
Andrew Fesnak, MD
Carl H. June, MD
Taku Kambayashi, MD, PhD
Bruce L. Levine, PhD
Daniel J. Powell, Jr., PhD
Don L. Siegel, MD, PhD

Adjunct Faculty

Margaret Keller, PhD
Senior Director, National Molecular and Genomics Laboratories Director, American Rare Donor Program
Sandra Nance, MS, MT (ASCP) SBB
Emeritus Senior Director, Immunohematology Reference Laboratory (IRL), Penn-Jersey Region, American Red Cross Blood Services

Contact

Nicole A. Aqui, MD
Director, Division of Transfusion Medicine & Therapeutic Pathology
215-615-4344
Aqui@pennmedicine.upenn.edu


Caitlin Cahill, RN, MSN, MBA
Administrative Director, Division of Transfusion Medicine & Therapeutic Pathology
215-662-6977
Caitlin.Cahill@pennmedicine.upenn.edu